The second half of 2019 is in full swing, and August brought along a pair of critical announcements in the marijuana investment market.
The fallout from the scandal surrounding CannTrust Holdings (NYSE:CTST,TSX:TRST) continued as a provincial retailer decided to return all the product from the company.
Across the border in the US, a conversation between the Department of Justice (DOJ) and industry leading multi-state operators (MSOs) may offer a different perspective on the relationship between the federal agency and the cannabis market.
OCS returns all CannTrust marijuana
Last month, the Ontario Cannabis Store (OCS), a provincial distributor and store, elected to issue a return of product to troubled marijuana producer CannTrust Holdings.
This decision was born out of operational wrongdoings from CannTrust. In July, Health Canada, the country’s regulator for the cannabis industry, found that the company had been growing cannabis in unlicensed rooms at its Pelham, Ontario, facility.
CannTrust confirmed to the Investing News Network (INN) that all the product being returned by the OCS was produced in its unlicensed rooms.
In an email to INN, an OCS spokesperson said the decision to return the product was “consistent with the OCS’ obligation to operate its business in a responsible manner.”
During the month of August, shares of CannTrust continued to be affected by its problems. As of Wednesday (August 28), shares of the company in New York and Toronto were down by 23.39 percent and 22.65 percent, respectively.
Companies embrace DOJ interactions
As part of the quarterly earnings season, Charlie Bachtell, co-founder and CEO of Cresco Labs (CSE:CL,OTCQX:CRLBF), told investors that his company’s recent interactions with the DOJ — as part of an antitrust acquisition review — are a positive sign for the US marijuana space.
“The fact that a federal agency is reviewing (a mergers and acquisitions) transaction in this industry must be seen as validation,” Bachtell said during a call discussing Cresco Labs’ second quarter results.
“They are acknowledging the existence of this industry and running our transaction through the same process as traditional industries,” he said.
The Illinois-based MSO is attempting to complete its planned acquisition of Origin House (CSE:OH,OTCQX:ORHOF), a move designed to offer Cresco Labs a unique entry point into the California cannabis state program.
Don’t forget to follow us @INN_Cannabis for real-time news updates!
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.
Editorial Disclosure: 4Front Ventures is a client of the Investing News Network. This article is not paid-for content.
Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (FSE: L0MA) (“Nextleaf”, “OILS”, or the “Company”), the world’s most innovative cannabis processor, is pleased to announce the initial order of Nextleaf’s Rapid Emulsion Technology by OILS™ (“Rapid”) THC and CBD to cannabis-infused beverage manufacturer, BevCanna Enterprises Inc. (“BevCanna”).
With this initial order, Nextleaf’s Rapid concentrate becomes one of BevCanna’s preferred ingredients, available for use in both their brands and their partner brands. Rapid is Nextleaf’s patent pending delivery technology.
Both locations expand access to the state’s widest-ranging inventory of medical cannabis products for Central Florida patients
Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today the opening of two brand-new Central Florida dispensaries. The new Clearwater and Tampa locations mark the Company’s 81 st and 82 nd nationwide, respectively, widening patient access to Florida’s largest and broadest assortment of high-quality medical cannabis products.
Philip Young, CEO and Director of Lobe, stated, “We are honored to welcome Bart to our Advisory Board. His first-hand experience on and off the field are tremendously valuable as we continue our research involving mild traumatic brain injuries and PTSD. These issues are prevalent in contact sports and we believe that athletes will play a prominent role in the continued acceptance of psychedelic medicines as legitimate treatment. We look forward to working with Bart as we seek to forge long-term strategic relationships.”